01/01/2013
Previous studies have suggested that BRCA mutation carriers with ovarian cancer have better survival rates than women who are not carriers. Researchers in Canada and the US sought to investigate long-term survival (10 years post diagnosis) in BRCA mutation carriers. Their results show that “for women with invasive ovarian cancer, the short-term survival advantage of carrying a BRCA1 or BRCA2 mutation does not lead to a long-term survival benefit.” The research was published in the Journal of the National Cancer Institute.
Click here for the abstract.
